BMS Earnings Beat Estimates, But Opdivo Sales Slide Continues
Executive Summary
The company believes the PD-1 inhibitor’s recent declines will be reversed through new indications, providing revenue growth along with other new products by the time Revlimid faces generics in 2022.
You may also be interested in...
A Rocky First Quarter For Big Pharma Stocks
Big pharma stocks, with few exceptions, saw big declines in valuation in the quarter amid the COVID-19 stock market rollercoaster, but pharma outperformed the S&P 500, showing the industry's resiliency in a global health crisis.
Yes For Shionogi But No For Lilly In Latest EMA Recommendations
The European Medicines Agency says that Shionogi’s novel antibiotic, Fetcroja, should be approved for use across Europe but that Lilly's migraine drug, Emgality, should not be authorized for the extended indication of episodic cluster headache.
Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.